• About us
• Contact

Advertisement

Product › Details

OP-233 (formerly TAK-233, Outpost Medicine / Takeda)

	Next higher product group	urological drug_o
	Status	2016-03-14 development pc existent

Record changed: 2023-07-10

Advertisement

More documents for pharmaceutical

• [1] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
• [2] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
• [3] Asahi Kasei Bioprocess. (4/11/24). "Press Release: Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development". Düsseldorf, Tokyo & New York, NY....
• [4] Boehringer Ingelheim. (4/9/24). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets". Ingelheim & Shanghai....
• [5] Seaport Therapeutics. (4/9/24). "Press Release: Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines". Boston, MA....
• [6] Pantherna Therapeutics GmbH / Wacker. (4/5/24). "Press Release: Pantherna and Wacker Intensify Collaboration in the Development and Production of mRNA Biopharmaceuticals". Munich & Hennigsdorf....
• [7] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
• [8] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
• [9] EnteroBiotix Ltd.. (4/4/24). "Press Release: EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials". Glasgow....
• [10] EnteroBiotix Ltd.. (4/3/24). "Press Release: EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)". Glasgow....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.